A peer-reviewed, evidence-based journal that promotes clinical development and metabolic insights in total bariatric patient care for the healthcare professional
Issue link: http://bariatrictimes.epubxp.com/i/800348
4 Bariatric Times • March 2017 i ntracranial pressure (ICP), release of vasopressin, and among other side effects, decreased renal function. A clear acute example o f it is the abdominal compartment syndrome and a clear chronic example of it is morbid obesity and pseudotumor cerebri. I look forward to see many of you at the annual meeting of Society of American Gastrointestinal and Endoscopic Surgeons ( SAGES) and join us in celebrating the 20 year anniversary of the Fellowship Council. Sincerely, Raul J. Rosenthal, MD, FACS, FASMBS REFERENCES 1. Hutter MM, Schirmer BD, Jones DB, et al. First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg. 2 011;254(3):410–420; discussion 420–422. 5. DeMaria EJ, Pate V, Warthen M, Winegar DA. Baseline data from American Society for Metabolic and Bariatric Surgery-designated Bariatric Surgery Centers of Excellence using the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis. 2 010;6(4):347–355. A Message from Dr. Raul Rosenthal continued... A Message from Dr. Christopher Still continued... p rocess in which the patient and physician weigh the risks/benefits will ensure an informed decision about drug choice. A wareness of the obesity epidemic is increasing among the healthcare community as a whole but I believe there is still a gap in e ducation about these known contributors to obesity, particularly drug-induced weight gain. Education and awareness go a long way. I n my practice, we have a handout for patients to share with their primary care and other physicians outlining which drugs have been associated with weight gain or weight loss hindrance. I also believe in fostering good communication with the patient's other physicians because getting everyone on the same page can only improve care. S incerely, Christopher Still, DO, FACN, FACP REFERENCES 1. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–362. 2. Ness-Abramof RApovian CM. Drug-induced weight gain. Drugs T oday (Barc). 2005;41(8):547–555. 3. Black C, Donnelly P, McIntyre L, Royle P, Shepherd JJ, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2007, Issue 2. Art. No.: CD004654. 4. Domecq JP, et al. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(2):363–370. Letter to the Editor Submissions Bariatric Times welcomes letters for possible publication. Letters should be no more than 500 words and five references. Letters that comment on a Bariatric Times article will be considered if they are received within two months of the time the article was published. All letters are reviewed by the editors and are selected based upon interest, timeliness, and pertinence, as determined by the editors. Send letters to: Angela Saba at email@example.com or mail to: Angela Saba, Bariatric Times, Matrix Medical Communications, 1595 Paoli Pike, Suite 201, West Chester, PA 19380. Include the following statement with the letter:"The undersigned author transfers all copyright ownership of the enclosed/attached letter to Matrix Medical Communications in the event the work is published. The undersigned author warrants that the letter is original, is not under consideration by another journal, and has not been previously published. I sign for and accept responsibility for releasing this material on behalf of any and all co-authors."